Protein aggregation is the major challenge encountered during manufacturing, storage and transportation of biopharmaceuticals (1, 2). Our objective was to evaluate the effect of twoßcyclodextrins derivatives: (KLEPTOSE® HPB hydroxypropyl-ß-cyclodextrin, with MS=0.65) and (KLEPTOSE® HP hydroxypropyl-ß-cyclodextrin, with MS=0.9) on two biologic drugs (Infliximab and Etanercept) aggregation using high-throughput formulation screening (iFormulate™) and nanoDSF (Differential Scanning Fluorimetry) (3, 4).
Products Used in this Publication
Dimeric fusion protein
